US EditionEuroPCR 2025: Myval shows promise in latest comparative studies against contemporary TAVI platforms - Cardiovascular News
Summary by Cardiovascular News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
EuroPCR 2025: Myval shows promise in latest comparative studies against contemporary TAVI platforms - Cardiovascular News
Patrick W Serruys New data comparing the Myval transcatheter aortic valve implantation (TAVI) system (Meril Life Sciences) to contemporary TAVI platforms, have shown that the device continues to measure favourably against its competitor valves. One-year clinical and haemodynamic outcomes from the randomised LANDMARK trial were shared at EuroPCR 2025 (20–23 May, Paris, France)—comparing the balloon-expandable system to both Sapien (Edwards Lifesc…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
